These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

138 related items for PubMed ID: 3201650

  • 21. Modulation of sensitivity to transforming growth factor-beta 1 (TGF-beta 1) and the level of type II TGF-beta receptor in LNCaP cells by dihydrotestosterone.
    Kim IY, Zelner DJ, Sensibar JA, Ahn HJ, Park L, Kim JH, Lee C.
    Exp Cell Res; 1996 Jan 10; 222(1):103-10. PubMed ID: 8549651
    [Abstract] [Full Text] [Related]

  • 22. Estramustine-binding protein (EMBP) content in four different cell lines and its correlation to estramustine induced metaphase arrest.
    Eklöv S, Mahdy E, Wester K, Björk P, Malmström PU, Busch C, Nilsson S.
    Anticancer Res; 1996 Jan 10; 16(4A):1819-22. PubMed ID: 8712706
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Additive inhibitory effects of an androgen and the antiestrogen EM-170 on estradiol-stimulated growth of human ZR-75-1 breast tumors in athymic mice.
    Dauvois S, Geng CS, Lévesque C, Mérand Y, Labrie F.
    Cancer Res; 1991 Jun 15; 51(12):3131-5. PubMed ID: 2039992
    [Abstract] [Full Text] [Related]

  • 27. Aryl hydrocarbon receptor-mediated inhibition of LNCaP prostate cancer cell growth and hormone-induced transactivation.
    Morrow D, Qin C, Smith R, Safe S.
    J Steroid Biochem Mol Biol; 2004 Jan 15; 88(1):27-36. PubMed ID: 15026081
    [Abstract] [Full Text] [Related]

  • 28. Epidermal growth factor receptor activation in androgen-independent but not androgen-stimulated growth of human prostatic carcinoma cells.
    Sherwood ER, Van Dongen JL, Wood CG, Liao S, Kozlowski JM, Lee C.
    Br J Cancer; 1998 Mar 15; 77(6):855-61. PubMed ID: 9528825
    [Abstract] [Full Text] [Related]

  • 29. Transforming growth factor-beta1 is a mediator of androgen-regulated growth arrest in an androgen-responsive prostatic cancer cell line, LNCaP.
    Kim IY, Kim JH, Zelner DJ, Ahn HJ, Sensibar JA, Lee C.
    Endocrinology; 1996 Mar 15; 137(3):991-9. PubMed ID: 8603613
    [Abstract] [Full Text] [Related]

  • 30. [The effect of estramustine phosphate on carcinoma cell proliferation depends on the estrogen receptor status in the cytosol].
    Zgradić I.
    God Vojnomed Akad; 1987 Mar 15; 29():77-81. PubMed ID: 3505486
    [No Abstract] [Full Text] [Related]

  • 31. Role of prostatic basal cells in the regulation and suppression of human prostate cancer cells.
    Miniati DN, Chang Y, Shu WP, Peehl DM, Liu BC.
    Cancer Lett; 1996 Jul 12; 104(2):137-44. PubMed ID: 8665481
    [Abstract] [Full Text] [Related]

  • 32. Regulation of proliferation and production of prostate-specific antigen in androgen-sensitive prostatic cancer cells, LNCaP, by dihydrotestosterone.
    Lee C, Sutkowski DM, Sensibar JA, Zelner D, Kim I, Amsel I, Shaw N, Prins GS, Kozlowski JM.
    Endocrinology; 1995 Feb 12; 136(2):796-803. PubMed ID: 7530653
    [Abstract] [Full Text] [Related]

  • 33. Effect of hormones on growth and ATP content of a human prostatic carcinoma cell line, LNCaP-r.
    Hasenson M, Hartley-Asp B, Kihlfors C, Lundin A, Gustafsson JA, Pousette A.
    Prostate; 1985 Feb 12; 7(2):183-94. PubMed ID: 4048015
    [Abstract] [Full Text] [Related]

  • 34. The synthesis of 3H labelled steroid-nitrogen mustard derivatives and studies on their action in rat and human prostate.
    Symes EK, Milroy EJ.
    J Steroid Biochem; 1982 Jul 12; 17(1):23-30. PubMed ID: 7109589
    [Abstract] [Full Text] [Related]

  • 35. The effect of estramustine, nor-nitrogen mustard and tauromustine on macromolecular labelling in the human prostatic tumour cell line 1013L.
    Kruse E, Hartley-Asp B.
    Pharmacol Toxicol; 1989 Jan 12; 64(1):9-13. PubMed ID: 2755916
    [Abstract] [Full Text] [Related]

  • 36. Synergistic effect of estramustine and [3'-keto-Bmtl]-[Val2]-cyclosporine (PSC 833) on the inhibition of androgen receptor phosphorylation in LNCaP cells.
    Wang LG, Liu XM, Budman DR, Kreis W.
    Biochem Pharmacol; 1999 Oct 01; 58(7):1115-21. PubMed ID: 10484069
    [Abstract] [Full Text] [Related]

  • 37. Treatment of oral estramustine phosphate (Estracyt) in prostatic carcinoma: influences on lipid and carbohydrate metabolism.
    Gustafson A, Persson B, Tisell LE, Wiklund O, Ohlson R.
    Invest Urol; 1977 Nov 01; 15(3):220-4. PubMed ID: 591268
    [Abstract] [Full Text] [Related]

  • 38. Resistance to the antimitotic drug estramustine is distinct from the multidrug resistant phenotype.
    Speicher LA, Sheridan VR, Godwin AK, Tew KD.
    Br J Cancer; 1991 Aug 01; 64(2):267-73. PubMed ID: 1892755
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Differential sensitivity of hormone-responsive and unresponsive human prostate cancer cells (LNCaP) to tumor necrosis factor.
    Zhao X, van Steenbrugge GJ, Schröder FH.
    Urol Res; 1992 Aug 01; 20(3):193-7. PubMed ID: 1615580
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.